Related Experiment Video
Updated: Jun 6, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Gene therapy for Parkinson's disease: where are we now and where are we going?
John Forsayeth1, Krystof S Bankiewicz, Michael J Aminoff
1Department of Neurological Surgery, University of California-San Francisco, CA 94110-0555, USA.
Abstract:
The number of patients worldwide who have received some kind of gene therapy is now in the thousands. A subset of that number have received intracranial injections of adeno-associated viruses encoding various therapeutic genes directed at ameliorating Parkinson's disease (PD). In this article we briefly examine the current status of Phase I and Phase II trials of gene therapy for PD and preview some of the improvements in delivery technology that promise to make adeno-associated-virus-based gene therapy for PD safer and more accessible to interventional neurologists around the world.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson Disease ll: Pathophysiology
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Gene Therapy
Gene Therapy
Parkinson Disease l: Introduction
